Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- -Sector
- $72.3952W High
- $56.0252W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vanguard Tax Managed Fund FTSE Developed Markets ETF has traded between a low of $56.02 and a high of $72.39, highlighting its annual price range. Buy and sell Vanguard Tax Managed Fund FTSE Developed Markets ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Most Recent News
Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Alamar Biosciences launches national study analyzing 21,000 plasma samples to advance Alzheimer's biomarkers.
Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...

Alamar Biosciences launches national study using blood tests to advance Alzheimer's biomarker research.
Alamar Biosciences has partnered with leading U.S. universities to launch a nationwide proteomics study analyzing around 21,000 plasma samples from 10,000 Alzheimer's and related dementia patients. Using its NULISAseq™ Neuro 220 test kit, the project...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.